TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $180,615 | -73.9% | 20,203 | -55.1% | 0.00% | -71.4% |
| Q2 2023 | $691,247 | -38.2% | 45,003 | -9.5% | 0.01% | -36.4% |
| Q1 2023 | $1,117,822 | +7.4% | 49,703 | +0.4% | 0.02% | +10.0% |
| Q4 2022 | $1,041,049 | +9.6% | 49,503 | +28.5% | 0.02% | +5.3% |
| Q3 2022 | $950,000 | +157.5% | 38,515 | +153.4% | 0.02% | +171.4% |
| Q2 2022 | $369,000 | -20.6% | 15,200 | -18.3% | 0.01% | +40.0% |
| Q1 2021 | $465,000 | -15.0% | 18,615 | -7.0% | 0.01% | -16.7% |
| Q4 2020 | $547,000 | – | 20,015 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |